Skip to main content
. Author manuscript; available in PMC: 2015 Jan 17.
Published in final edited form as: N Engl J Med. 2014 May 31;371(3):213–223. doi: 10.1056/NEJMoa1400376

Figure 3. Best Response to Therapy, as Assessed by Independent Reviewers and by Investigators.

Figure 3

Shown are rates of patients’ best response to therapy, according to independent assessment (Panel A) and investigator assessment (Panel B) with respect to complete response (CR), complete response with incomplete hematopoietic recovery (CRi), partial response (PR), partial response with lymphocytosis (PR+L), stable disease (SD), and progressive disease (PD). Data were unknown, missing, or could not be evaluated for 5 patients in the ibrutinib group in both the independent assessment and the investigator assessment and for 15 patients in the ofatumumab group in the independent assessment and 17 patients in the group in the investigator assessment.